Chapter 17
New Agents for Treatment of Dyslipidemia
Vinaya Simha,
Vinaya Simha
Associate Professor, Division of Endocrinology, Diabetes, Metabolism and nutrition, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorVinaya Simha,
Vinaya Simha
Associate Professor, Division of Endocrinology, Diabetes, Metabolism and nutrition, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorBook Editor(s):Adrian Vella MD FRCP(Edin.),
Adrian Vella MD FRCP(Edin.)
Division of Diabetes, Endocrinology & Metabolism, Earl and Annette R. McDonough Professor, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorFirst published: 05 November 2021
Summary
Diabetes mellitus is associated with elevated risk for atherosclerotic cardiovascular disease (ASCVD), and statin therapy has been shown to reduce this risk. ASCVD is leading cause for morbidity and mortality in patients with type 2 diabetes, and heartening trend of decreasing ASCVD mortality in the overall population is unfortunately not seen in patients with diabetes. This chapter summarizes the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in regulation of circulating cholesterol levels, clinical trials of PCSK9 inhibitors, and their optimal use in clinical practice, followed by a brief discussion on emerging triglyceride-lowering therapies. The net effect of PCSK9 is reduced recycling of low density lipoprotein (LDL) receptor to the hepatocyte membrane and resultant decrease in clearance of circulating LDL particles. The available data clearly show the ability of this class of lipid-lowering drugs to safely and effectively reduce the level of LDL-cholesterol and other atherogenic lipoproteins leading to reduced incidence of major vascular events.
References
- Hu FB , Stampfer MJ , Solomon CG , Liu S , Willett WC , Speizer FE et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up . Arch Intern Med . 2001 ; 161 ( 14 ): 1717 – 1723 .
- Fox CS , Golden SH , Anderson C , Bray GA , Burke LE , de Boer IH et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association . Circulation . 2015 ; 132 ( 8 ): 691 – 718 .
- Yeh RW , Sidney S , Chandra M , Sorel M , Selby JV , Go AS . Population trends in the incidence and outcomes of acute myocardial infarction . N Engl J Med . 2010 ; 362 ( 23 ): 2155 – 2165 .
- Rawshani A , Rawshani A , Franzen S , Eliasson B , Svensson AM , Miftaraj M et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes . N Engl J Med . 2017 ; 376 ( 15 ): 1407 – 1418 .
- Cholesterol Treatment Trialists C , Kearney PM , Blackwell L , Collins R , Keech A , Simes J et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis . Lancet . 2008 ; 371 ( 9607 ): 117 – 125 .
- Grundy SM , Stone NJ , Bailey AL , Beam C , Birtcher KK , Blumenthal RS et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol . Circulation . 2018 :CIR0000000000000625.
- Cholesterol Treatment Trialists C , Fulcher J , O'Connell R , Voysey M , Emberson J , Blackwell L et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials . Lancet . 2015 ; 385 ( 9976 ): 1397 – 1405 .
- Jacobs MJ , Kleisli T , Pio JR , Malik S , L'Italien GJ , Chen RS et al. Prevalence and control of dyslipidemia among persons with diabetes in the United States . Diabetes Res Clin Pract . 2005 ; 70 ( 3 ): 263 – 269 .
- Hirano T . Pathophysiology of diabetic dyslipidemia . J Atheroscler Thromb . 2018 ; 25 ( 9 ): 771 – 782 .
- Bhatt DL , Steg PG , Miller M , Brinton EA , Jacobson TA , Ketchum SB et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia . N Engl J Med . 2019 ; 380 ( 1 ): 11 – 22 .
- Sacks FM , Carey VJ , Fruchart JC . Combination lipid therapy in type 2 diabetes . N Engl J Med . 2010 ; 363 ( 7 ): 692 – 694 ; author reply 4–5.
- Cannon CP , Blazing MA , Giugliano RP , McCagg A , White JA , Theroux P et al. Ezetimibe added to statin therapy after acute coronary syndromes . N Engl J Med . 2015 ; 372 ( 25 ): 2387 – 2397 .
- Abifadel M , Varret M , Rabes JP , Allard D , Ouguerram K , Devillers M et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia . Nat Genet . 2003 ; 34 ( 2 ): 154 – 156 .
- Horton JD , Cohen JC , Hobbs HH . PCSK9: a convertase that coordinates LDL catabolism . J Lipid Res . 2009 ; 50 ( Suppl ): S172 – 177 .
- Tavori H , Rashid S , Fazio S . On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects . Atherosclerosis . 2015 ; 238 ( 2 ): 264 – 270 .
- Sabatine MS . PCSK9 inhibitors: clinical evidence and implementation . Nat Rev Cardiol . 2019 ; 16 ( 3 ): 155 – 165 .
- Maxwell KN , Breslow JL . Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype . Proc Natl Acad Sci USA . 2004 ; 101 ( 18 ): 7100 – 7105 .
- Rashid S , Curtis DE , Garuti R , Anderson NN , Bashmakov Y , Ho YK et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9 . Proc Natl Acad Sci USA . 2005 ; 102 ( 15 ): 5374 – 5379 .
- Cohen J , Pertsemlidis A , Kotowski IK , Graham R , Garcia CK , Hobbs HH . Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9 . Nat Genet . 2005 ; 37 ( 2 ): 161 – 165 .
- Cohen JC , Boerwinkle E , Mosley TH , Jr. , Hobbs HH . Sequence variations in PCSK9, low LDL, and protection against coronary heart disease . N Engl J Med . 2006 ; 354 ( 12 ): 1264 – 1272 .
- Kathiresan S , Myocardial Infarction Genetics C. A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction . N Engl J Med . 2008 ; 358 ( 21 ): 2299 – 2300 .
- Sabatine MS , Giugliano RP , Wiviott SD , Raal FJ , Blom DJ , Robinson J et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events . N Engl J Med . 2015 ; 372 ( 16 ): 1500 – 1509 .
- Robinson JG , Farnier M , Krempf M , Bergeron J , Luc G , Averna M et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events . N Engl J Med . 2015 ; 372 ( 16 ): 1489 – 1499 .
- Bohula EA , Giugliano RP , Leiter LA , Verma S , Park JG , Sever PS et al. Inflammatory and Cholesterol Risk in the FOURIER Trial . Circulation . 2018 ; 138 ( 2 ): 131 – 140 .
- Raal FJ , Hovingh GK , Blom D , Santos RD , Harada-Shiba M , Bruckert E et al. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study . Lancet Diabetes Endocrinol . 2017 ; 5 ( 4 ): 280 – 290 .
- Robinson JG , Rosenson RS , Farnier M , Chaudhari U , Sasiela WJ , Merlet L et al. Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials . J Am Coll Cardiol . 2017 ; 69 ( 5 ): 471 – 482 .
- Giugliano RP , Mach F , Zavitz K , Kurtz C , Im K , Kanevsky E et al. Cognitive function in a randomized trial of evolocumab . N Engl J Med . 2017 ; 377 ( 7 ): 633 – 643 .
- Sabatine MS , Giugliano RP , Keech AC , Honarpour N , Wiviott SD , Murphy SA et al. Evolocumab and clinical outcomes in patients with cardiovascular disease . N Engl J Med . 2017 ; 376 ( 18 ): 1713 – 1722 .
- Schwartz GG , Steg PG , Szarek M , Bhatt DL , Bittner VA , Diaz R et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome . N Engl J Med . 2018 ; 379 ( 22 ): 2097 – 2107 .
- Handelsman Y , Lepor NE . PCSK9 Inhibitors in lipid management of patients with diabetes mellitus and high cardiovascular risk: a review . J Am Heart Assoc . 2018 ; 7 ( 13 ): e008953 .
- Leiter LA , Muller-Wieland D , Baccara-Dinet MT , Letierce A , Samuel R , Cariou B . Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials . Diabet Med . 2018 ; 35 ( 1 ): 121 – 130 .
- Blom DJ , Koren MJ , Roth E , Monsalvo ML , Djedjos CS , Nelson P et al. Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome . Diabetes Obes Metab . 2017 ; 19 ( 1 ): 98 – 107 .
- Sattar N , Preiss D , Robinson JG , Djedjos CS , Elliott M , Somaratne R et al. Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data . Lancet Diabetes Endocrinol . 2016 ; 4 ( 5 ): 403 – 410 .
- Leiter LA , Zamorano JL , Bujas-Bobanovic M , Louie MJ , Lecorps G , Cannon CP et al. Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II . Diabetes Obes Metab . 2017 ; 19 ( 7 ): 989 – 996 .
- Leiter LA , Cariou B , Muller-Wieland D , Colhoun HM , Del Prato S , Tinahones FJ et al. Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial . Diabetes Obes Metab . 2017 ; 19 ( 12 ): 1781 – 1792 .
- Ray KK , Leiter LA , Muller-Wieland D , Cariou B , Colhoun HM , Henry RR et al. Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial . Diabetes Obes Metab . 2018 ; 20 ( 6 ): 1479 – 1489 .
- Lorenzatti AJ , Eliaschewitz FG , Chen Y , Lu J , Baass A , Monsalvo ML et al. Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Primary results of the BERSON clinical trial . Diabetes Obes Metab . 2019 ; 21 ( 6 ): 1455 – 1463 .
- Sabatine MS , Leiter LA , Wiviott SD , Giugliano RP , Deedwania P , De Ferrari GM et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial . Lancet Diabetes Endocrinol . 2017 ; 5 ( 12 ): 941 – 950 .
- Moriarty PM , Parhofer KG , Babirak SP , Cornier MA , Duell PB , Hohenstein B et al. Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial . Eur Heart J . 2016 ; 37 ( 48 ): 3588 – 3595 .
- Giugliano RP , Pedersen TR , Park JG , De Ferrari GM , Gaciong ZA , Ceska R et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial . Lancet . 2017 ; 390 ( 10106 ): 1962 – 1971 .
- Ference BA , Robinson JG , Brook RD , Catapano AL , Chapman MJ , Neff DR et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes . N Engl J Med . 2016 ; 375 ( 22 ): 2144 – 2153 .
- Ray KK , Wright RS , Kallend D , Koenig W , Leiter LA , Raal FJ et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol . N Engl J Med . 2020 ; 382 ( 16 ): 1507 – 1519 .
- Landlinger C , Pouwer MG , Juno C , van der Hoorn JWA , Pieterman EJ , Jukema JW et al. The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice . Eur Heart J . 2017 ; 38 ( 32 ): 2499 – 2507 .
- Ding Q , Strong A , Patel KM , Ng SL , Gosis BS , Regan SN et al. Permanent alteration of PCSK9 with in vivo; CRISPR-Cas9 genome editing . Circ Res . 2014 ; 115 ( 5 ): 488 – 492 .
- Laufs U , Banach M , Mancini GBJ , Gaudet D , Bloedon LT , Sterling LR et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance . J Am Heart Assoc . 2019 ; 8 ( 7 ): e011662 .
- Doi H , Kugiyama K , Oka H , Sugiyama S , Ogata N , Koide SI et al. Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism . Circulation . 2000 ; 102 ( 6 ): 670 – 676 .
- Chait A , Ginsberg HN , Vaisar T , Heinecke JW , Goldberg IJ , Bornfeldt KE . Remnants of the triglyceride-rich lipoproteins, diabetes, and cardiovascular disease . Diabetes . 2020 ; 69 ( 4 ): 508 – 516 .
- Zheng XY , Liu L . Remnant-like lipoprotein particles impair endothelial function: direct and indirect effects on nitric oxide synthase . J Lipid Res . 2007 ; 48 ( 8 ): 1673 – 1680 .
- Gaudet D , Alexander VJ , Baker BF , Brisson D , Tremblay K , Singleton W et al. Antisense inhibition of apolipoprotein c-iii in patients with hypertriglyceridemia . N Engl J Med . 2015 ; 373 ( 5 ): 438 – 447 .
- Alexander VJ , Xia S , Hurh E , Hughes SG , O'Dea L , Geary RS et al. N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels . Eur Heart J . 2019 ; 40 ( 33 ): 2785 – 2796 .
- The TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute , Crosby J , Peloso GM , Auer PL et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease . N Engl J Med . 2014 ; 371 ( 1 ): 22 – 31 .
- Dewey FE , Gromada J , Shuldiner AR . Variants in ANGPTL4 and the risk of coronary artery disease . N Engl J Med . 2016 ; 375 ( 23 ): 2305 – 2306 .
